Tomassen, Jori
den Braber, Anouk
van der Lee, Sven J.
Reus, Lianne M.
Konijnenberg, Elles
Carter, Stephen F.
Yaqub, Maqsood
van Berckel, Bart N.M.
Collij, Lyduine E.
Boomsma, Dorret I.
de Geus, Eco J.C.
Scheltens, Philip
Herholz, Karl
Tijms, Betty M.
Visser, Pieter Jelle
Funding for this research was provided by:
EU/EFPIA Innovative Medicines Initiative Joint Undertaking EMIF (n°115372)
Article History
Received: 8 June 2022
Revised: 14 October 2022
Accepted: 19 October 2022
First Online: 15 December 2022
Declarations
:
: The National Research Ethics Service Committee North West—Greater Manchester South performed ethical approval of the study for Manchester. The Medical Ethics Review Committee of the VU University Medical Center performed approval of the study for Amsterdam. Each participant gave written informed consent. The research is performed according to the principles of the Helsinki Declaration of 1975 and in accordance with the Medical Research Involving Human Subjects Act and codes on ‘good use’ of clinical data and biological samples as developed by the Dutch Federation of Medical Scientific Societies.
: Not applicable.
: J.T., A.dB., S.J.vdL., L.M.R., E.K., S.F.C., M.Y., B.N.M.vB., L.E.C., D.I.B., E.J.C.dG., K.H., B.M.T. and PJ.V. declare that they have no competing interests. Ph.S. has received consultancy fees (paid to the institution) from AC Immune, Brainstorm Cell, EIP, ImmunoBrain Checkpoint, Genentech, Novartis and Novo Nordisk. He is PI of studies with AC Immune, FUJI-film/Toyama, UCB, and Vivoryon. He is a part-time employee of Life Sciences Partners Amsterdam.